Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
A Phase Ib Vaccine Trial Evaluating the Safety and Immunogenicity of HIV Lipopeptides by Two Administration Routes (Intramuscular And Intradermal) in Healthy Adult Volunteers. ANRS VAC16 Trial
研究概览
详细说明
Dose-sparing strategies that use intradermal (ID) delivery of vaccines may be one approach for improving a vaccines immunogenicity and reducing the cost of vaccines.
In this study, 68 HIV-negative healthy adult volunteers, 21-55 years old, all belonging to the "Volunteers for a Vaccine" network set up by ANRS, were randomized to receive at weeks 0, 4, and 12, either 3 IM doses of 0.5 ml of LIPO-4 containing 500 µg of each peptide (n= 35 volunteers), or 3 ID doses of 0.1 ml, containing 100 µg of each peptide (n=33 volunteers). Total follow-up was 48 weeks. Safety was assessed clinically and by laboratory tests. Participants were given diary cards to record adverse events. HIV-1 immune responses were assessed by ELISPOT and lymphoproliferative assay at weeks 0, 2, 6, 14, 24, and 48
研究类型
注册
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Paris、法国、75014
- Hopital Cochin Centre Cochin-Pasteur d'Essais vaccinaux
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- HIV uninfected
- Acceptable methods of contraception for females of reproductive potential
- Good general health
- Signed written inform consent
Exclusion Criteria:
- Risk to be infected by HIV virus
- Uveitis, chronic lyme disease, active syphilis, active mycobacterial diseases or sarcoidosis
- Autoimmune disease or immunodeficiency
- Medical history of food allergy, Lyell's or Steven Johnson's disease, unstable asthma
- Active, generalized eczema or chronic urticaria
- Blood products within 2 months prior to first study vaccine administration
- HIV vaccines in prior HIV vaccine trial or participation in an immunomodulator study
- Vaccines within 30 days prior to first study vaccine administration
- Pregnant
- Long-term immunosuppressive or immunomodulator medications or within 6 months to first study vaccine administration
- Blood transfusion within 6 months to first study vaccine administration
- Treated with extracted pituitary hormones
学习计划
研究是如何设计的？
设计细节
- 主要用途：预防
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
研究衡量的是什么？
主要结果指标
结果测量 |
|---|
|
Clinical and biological safety (over or equal to degree two of a adverse event grading scale) of LIPO-4 by ID and IM routes during the study
|
次要结果测量
结果测量 |
|---|
|
Comparaison of CD4 positive cells responses using
|
|
lymphoprolifération test and CD8 positive cells responses using the capacity of these cells to synthesize IFN following stimulation with peptides of interest (ELISPOT IFN test) following IM or ID administration at weeks 2, 6, 14, 24, and 48
|
合作者和调查者
调查人员
- 首席研究员：Odile Launay, MD、Hopital Cochin Paris, Centre Cochin-Pasteur d'essais vaccinaux
- 研究主任：Christine Durier, MD、Inserm SC10
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
研究完成
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
艾滋病毒感染的临床试验
-
Hospital Clinic of Barcelona完全的
-
Rajavithi Hospital未知研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的免疫状态 | 研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的 HIV 病毒载量泰国
-
National Institute of Allergy and Infectious Diseases...完全的HIV-1 感染 | HIV抗体 | 中和抗体 | 病毒载量 | 单克隆抗体美国
-
AIDS Healthcare FoundationUniversity of California, Los Angeles完全的
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University of Bergen; Centre... 和其他合作者完全的
-
Hospital Universitari Vall d'Hebron Research InstituteGilead Sciences完全的
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixa完全的
Lipopeptides LIPO-4的临床试验
-
French National Agency for Research on AIDS and...Aventis Pharmaceuticals完全的
-
National Institute of Allergy and Infectious Diseases...ANRS, Emerging Infectious Diseases完全的